~EXPECTING NEWS~

[j$tops]

$COBI Compass Biotechnologies Inc. OTCQB

http://www.c-pharma.net/
Inquiries CONTACT:
Mr. Garth Likes, President/CEO, [e-mail],
Compass Biotechnologies /C-Pharma Inc.
Advanced Technology Center, 9650-20th Avenue,
Suite 131,
Edmonton, Alberta, [phone]
http://investorshub.advfn.com/boards/board.aspx?board_id=14494
Recent News!!!!
http://www.otcmarkets.com/stock/COBI/news
Recent Filings!!!
http://www.otcmarkets.com/stock/COBI/financials
Transfer Agent
Pacific Stock Transfer Co.
4045 South Spencer St., Suite 403
Las Vegas, NV, 89119
702-361-3033
http://www.pacificstocktransfer.com
[e-mail]
COBI share structure per TA
outstanding shares 20,655,629
Float: N/A
Authorized shares 100mil
On May 17, 2011, the shareholders' list showed 91 registered shareholders

NOTE: Cyplasin Biomedical Ltd., recently completed a name change to Compass Biotechnologies Inc (COBI:QB) to better reflect it new market strategy and Corporate mission. Additionally we have created a wholly owned subsidiary company called C-Pharma Compass Biotechnologies Inc (formerly Cyplasin Biomedical Inc) is a public biopharm--aceutical company (COBI.OB) focused on the commercialization of life-saving products targeted for sale in the multi-billion dollar global bio generics and biosimiliars market. The Company also has a private wholly owned
subsidiary company called C-Pharma which is charged with the development of a Hepatitis therapeutic vaccine franchise. To this effect Compass Biotech Inc., retains all rights to the previously held worldwide exclusive Hepatitis product licenses and other rights from the National Institutes of Health (NIH) but will now focus on the bio generic/ biosimiliar product opportunities within the Hepatitis and other medical fields while C-Pharma will focus on the hepatitis C vaccine market.
Hepatitis C background: Infection with the highly contagious hepatitis C virus ("HCV") has grown into a global epidemic, with over 250 million people infected with the virus worldwide - about 4% of the world's population. Because of the lack of a large-scale effort to contain the spread of this virus, the death rate from hepatitis C has surpassed that of HIV/AIDS, and will continue to get worse. Over 80% of people infected with HCV go on to a chronic infection phase. Chronic infection with HCV leads to liver fibrosis, cirrhosis, liver failure, and liver cancer, and is the leading cause of liver transplantation in the Western World. The current combination drug therapies have limited activity and no Hepatitis C treatment or preventative vaccine or has been commercialized to date. C-Pharma’s Corporate Mission: Hepatitis C treatment C-Pharma is on a mission to develop and commercialize less expensive and better tolerated anti-viral therapies and a preventative vaccine made from virus-like particles (VLPs). VLPs are a groundbreaking, new vaccine technology that activates the immune system to prevent and treat HCV diseases. The nearly 100% effective Gardasil® marketed by Merck is a VLP-based vaccine developed against human papillomavirus (HPV) infection and the 3 marketed hepatitis B vaccines are VLP-based vaccines. VLPs are self-assembled protein spheres made from the viral proteins that make up the viral structure. These three dimensional, multi-antigen particles have already proven to be safer and more effective preventative vaccines and may be used as anti-viral therapies as well. Compass Biotechnologies Inc., the parent of C-Pharma is the only company with a VLP vaccine under development to prevent and eliminate HCV infection. Products to Fight HCV Infection
Products
The Company is now preparing to commercialize
the following products:

C-Virin – is a convenient, once-a-day oral formulation of ribavirin USP
.
C-Pegferon –is our brand of long-lasting, pegylated-interferon-alpha-2b. This product and C-Virin will be used together for the treatment of genotype 1, 2, 3, and 4 strains of hepatitis C virus.

C-Vaxin – is a bivalent VLP vaccine and adjuvant combination designed to be used for the prevention of genotype-1 HCV infections or as an active-specific immunotherapy of chronic HCV disease
.
C-Immune – is a genotype-1-specific human immune globulin (antibody) product made by donor plasma fractionation, used for passive immunotherapy of HCV patients who fail to respond to ribavirin and interferon, and will be developed for the prevention or delay of graft re-infection by HCV in liver transplant recipients whose livers have failed due to chronic HCV infection

Our Management Team

The Company’s management team, advisors and consultants possess a deep knowledge of the Company’s products and indications, and strong start-up company management experience.

Founder and Chairman of the Board of Directors, Dr. Joseph Sinkule is a serial entrepreneur and a 28-year biotech veteran with extensive biotech startup experience. Joe has taken several drug and recombinant protein products from discovery thru FDA approval and licensure. He was previously Sr. VP of R&D at a NASDAQ-listed biotech company and Director of Clinical Research at Immunex. Joe founded five other biotech companies and two CROs, and currently serves on the Boards of four healthcare companies.

Chief Executive Officer and Director, Garth Likes is the founder and CEO of Cyplasin Biomedical,and served as CEO and Board member of several public companies. Garth has the industry experience to successfully navigate the Company through financings, corporate operations, and overall management of this public company entity. Because of his prior business development experience, Garth will work with Seth Goldblum to manage the corporate partnering and corporate management activities.

Chief Business Officer, Seth Goldblum, MBA, is a biotech executive with 20 years of business development deal-making, finance and corporate management experience, particularly in the vaccine area. Seth and Garth will be a key contributors in the finance and corporate partnering areas. Seth will begin structuring the deal for out-licensing the preventive indication of the HCV vaccine to a major vaccine company.

The Company has begun recruiting additional staff including project management and administrative accounting positions, and is assembling a first-rate team of experienced biotech personnel that are readied for successful execution of the product development programs.

The Scientific Advisory Board of Cyplasin Biomedical will be assembled by Dr. Liang, one of world’s top experts on HCV infection and head of the Liver Disease Section of the NIH. Dr. Liang is the co-inventor of the Company's patented HCV VLP vaccine technology. Top-notched scientific expertise recruited to the SAB will help guide our direction by proving valuable technical and clinical input.

An industry-experienced Board of Directors from around the country will be recruited over the next 3-6 months to advise the management team and represent the shareholders of the Company. The Board will be comprised predominantly of independent experts contributing various expertise and insight as to overall management and value creation for the Company.

The Company is a Nevada corporation and will continue to be headquartered in Edmonton, Alberta Canada [Suite 131, Advanced Technology Center, 9650 20th Avenue, Edmonton, Alberta CANADA].